Literature DB >> 1929691

A model of lifetime osteoporosis impact.

E A Chrischilles1, C D Butler, C S Davis, R B Wallace.   

Abstract

The study goal was to use population-based data to model aspects of lifetime osteoporosis impact not previously studied, specifically: (1) to estimate person-years of fracture-related functional impairment against the trajectory of functional status in the general population; (2) jointly to consider hip, vertebral, and Colles' fractures in estimating the percent of women who will ever fracture; and (3) to estimate the lifetime number of fractures expected in a cohort of 10,000 50-year-old white postmenopausal women. The model estimates that 54% of 50-year-old women will sustain osteoporosis-related fractures during their remaining lifetimes. Beyond the functional impairment expected in similarly aged, unfractured women, osteoporosis-related fractures are estimated to cause 6.7% of women to become dependent in basic activities of daily living; 7.8% are expected to require nursing home care for an average of 7.6 years.

Entities:  

Mesh:

Year:  1991        PMID: 1929691

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  94 in total

1.  Transmission of force in the lumbosacral spine during backward falls.

Authors:  Carolyn Van Toen; Meena M Sran; Stephen N Robinovitch; Peter A Cripton
Journal:  Spine (Phila Pa 1976)       Date:  2012-04-20       Impact factor: 3.468

2.  Evaluation of trabecular microarchitecture in nonosteoporotic postmenopausal women with and without fracture.

Authors:  Richard Kijowski; Michael Tuite; Diane Kruger; Alejandro Munoz Del Rio; Michael Kleerekoper; Neil Binkley
Journal:  J Bone Miner Res       Date:  2012-07       Impact factor: 6.741

3.  Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date.

Authors:  Anthony B Hodsman; David A Hanley; Robert Josse
Journal:  CMAJ       Date:  2002-05-28       Impact factor: 8.262

4.  Age-related hip fractures in men: clinical spectrum and short-term outcomes.

Authors:  G Poór; E J Atkinson; D G Lewallen; W M O'Fallon; L J Melton
Journal:  Osteoporos Int       Date:  1995       Impact factor: 4.507

5.  Magnolol protects osteoblastic MC3T3-E1 cells against antimycin A-induced cytotoxicity through activation of mitochondrial function.

Authors:  Eun Mi Choi
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

Review 6.  The epidemiology of osteoporosis.

Authors:  Michael A Clynes; Nicholas C Harvey; Elizabeth M Curtis; Nicholas R Fuggle; Elaine M Dennison; Cyrus Cooper
Journal:  Br Med Bull       Date:  2020-05-15       Impact factor: 4.291

7.  Estimation of 10-year probability bone fracture in a selected sample of Palestinian people using fracture risk assessment tool.

Authors:  Mai B Aker; Adham S Abu Taha; Sa'ed H Zyoud; Ansam F Sawalha; Samah W Al-Jabi; Waleed M Sweileh
Journal:  BMC Musculoskelet Disord       Date:  2013-10-05       Impact factor: 2.362

Review 8.  Evaluation of therapeutic efficacy in osteoporosis.

Authors:  S Adami; S Ortolani; R Wasnich
Journal:  Osteoporos Int       Date:  1995-03       Impact factor: 4.507

9.  The diagnostic role of dual femur bone density measurement in low-impact fractures.

Authors:  Joseph C H Wong; Louise McEwan; Naomi Lee; Matthew R Griffiths; Nicholas A Pocock
Journal:  Osteoporos Int       Date:  2003-04-01       Impact factor: 4.507

10.  Pharmacological treatments for osteoporosis in very elderly people.

Authors:  Wei Mei Chua; Novoneel Nandi; Tahir Masud
Journal:  Ther Adv Chronic Dis       Date:  2011-07       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.